You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

308 Results
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Neoadjuvant, Palliative
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Palliative
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
ODB - General Benefit
  • flutamide
Oct 2016
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Adjuvant, Palliative
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Adjuvant, Palliative
Regimen
Regimen
Cancer Type:
Gynecologic, 
Vulva
Intent: Adjuvant, Palliative
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Adjuvant
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
ODB Limited Use
    lenalidomide - For the maintenance treatment of patients with newly diagnosed multiple myeloma, following ASCT, according to clinical criteria

Pages